New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways

References

• McGrath J Saha S Welham J El Saadi O MacCauley C Chant D A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology BMC Med 2004 2 13 15115547
   PubMed Web of Science ®Google Scholar
• Stilo SA Murray RM The epidemiology of schizophrenia: replacing dogma with knowledge Dialogues Clin Neurosci 2010 12 305 315 20954427
   PubMedGoogle Scholar
• DeLisi LE The significance of age of onset for schizophrenia Schizophren Bull 1992 18 209 215
   PubMed Web of Science ®Google Scholar
• Lieberman JA Stroup TS McEvoy JP Swartz MS Rosenheck RA Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 2005 353 12 1209 1223 16172203
   PubMed Web of Science ®Google Scholar
• Carpenter WTJr Buchanan RW Schizophrenia N Engl J Med 1994 330 10 681 690 8107719
   PubMed Web of Science ®Google Scholar
• Carlsson A Lindqvist M Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain Acta Pharmacol Toxicol 1963 20 140 144
   PubMedGoogle Scholar
• Andén NE Butcher SG Corrodi H Fuxe K Ungerstedt U Receptor activity and turnover of dopamine and noradrenaline after neuroleptics Eur J Pharmacol 1970 11 3 303 314 5477307
   PubMed Web of Science ®Google Scholar
• Stone JM Raffin M Morrison P McGuire PK Review: The biological basis of antipsychotic response in schizophrenia J Psychopharmacol 2010 24 7 953 964 19939865
   PubMed Web of Science ®Google Scholar
• Conley RR Buchanan RW Evaluation of treatment-resistant schizophrenia Schizophr Bull 1997 23 4 663 674 9366002
   PubMed Web of Science ®Google Scholar
• Hasan A Falkai P Wobrock T Lieberman J Glenthoj B World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance World J Biol Psychiatry 2012 13 318 378 22834451
   PubMed Web of Science ®Google Scholar
• Hasan A Falkai P Wobrock T Lieberman J Glenthoj B World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects World J Biol Psychiatry 2013 149 1 2 44 23216388
   PubMed Web of Science ®Google Scholar
• Javitt DC Management of negative symptoms of schizophrenia Curr Psychiatry Rep 2001 3 5 413 417 11559479
   PubMedGoogle Scholar
• Tamminga CA Buchanan RW Gold JM The role of negative symptoms and cognitive dysfunction in schizophrenia outcome Int Clin Psychopharmacol 1998 13 Suppl 3 S21 S26 9690966
   PubMed Web of Science ®Google Scholar
• Davé M Clozapine-related tardive dyskinesia Biol Psychiatry 1994 35 11 886 887 8054412
   PubMed Web of Science ®Google Scholar
• Ertugrul A Demir B Clozapine-induced tardive dyskinesia: a case report Prog Neuropsychopharmacol Biol Psychiatry 2005 29 4 633 635 15866369
   PubMed Web of Science ®Google Scholar
• López-Muñoz F Alamo C Cuenca E Shen WW Clervoy P Rubio G History of the discovery and clinical introduction of chlorpromazine Ann Clin Psychiatry 2005 17 3 113 135 16433053
   PubMedGoogle Scholar
• Altschule MD Use of chlorpromazine and reserpine in mental disorders N Engl J Med 1956 254 11 515 519 13297145
   PubMed Web of Science ®Google Scholar
• Creese I Burt DR Snyder SH Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs Science 1976 192 4238 481 483 3854
   PubMed Web of Science ®Google Scholar
• Seeman P Lee T Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons Science 1975 188 4194 1217 1219 1145194
   PubMed Web of Science ®Google Scholar
• Miyamoto S Duncan GE Marx CE Lieberman JA Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs Mol Psychiatry 2005 10 1 79 104 15289815
   PubMed Web of Science ®Google Scholar
• Stevens JR An anatomy of schizophrenia? Arch Gen Psychiatry 1973 29 2 177 189 4147475
   PubMed Web of Science ®Google Scholar
• Meltzer HY Simonovic M Gudelsky GA Phencyclidine-induced inhibition of rat prolactin secretion: increased portal blood dopamine Eur J Pharmacol 1985 110 1 143 146 4007050
   PubMed Web of Science ®Google Scholar
• Kane J Honigfeld G Singer J Meltzer H Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Arch Gen Psychiatry 1988 45 9 789 796 3046553
   PubMed Web of Science ®Google Scholar
• Meltzer HY Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia Psychopharmacology (Berl) 1989 99 Suppl S18 S27 2682729
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A Laruelle M Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies Eur Psychiatry 2005 20 1 15 27 15642439
   PubMed Web of Science ®Google Scholar
• Frankle WG Gil R Hackett E Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications Psychopharmacology (Berl) 2004 175 4 473 480 15083259
   PubMed Web of Science ®Google Scholar
• Bressan RA Erlandsson K Jones HM Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients Am J Psychiatry 2003 160 8 1413 1420 12900302
   PubMed Web of Science ®Google Scholar
• Kapur S Remington G Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient Biol Psychiatry 2001 50 11 873 883 11743942
   PubMed Web of Science ®Google Scholar
• Seeman P Atypical antipsychotics: mechanism of action Can J Psychiatry 2002 47 1 27 38 11873706
   PubMed Web of Science ®Google Scholar
• Meltzer HY McGurk SR The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia Schizophren Bull 1999 25 5 233 255
   Web of Science ®Google Scholar
• Marder SR Davis JM Chouinard G The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials J Clin Psychiatry 1997 58 12 538 546 9448657
   PubMed Web of Science ®Google Scholar
• Tollefson GD Sanger TM Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine Am J Psychiatry 1997 154 4 466 474 9090332
   PubMed Web of Science ®Google Scholar
• Keefe RS Silva SG Perkins DO Lieberman JA The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis Schizophr Bull 1999 25 2 201 222 10416727
   PubMed Web of Science ®Google Scholar
• Newcomer JW Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review CNS Drugs 2005 19 Suppl 1 1 93 15998156
   PubMed Web of Science ®Google Scholar
• Jones PB Barnes TR Davies L Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry 2006 63 10 1079 1087 17015810
   PubMed Web of Science ®Google Scholar
• Leucht S Cipriani A Spineli L Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis Lancet 2013 382 9896 951 962 23810019
   PubMed Web of Science ®Google Scholar
• Leucht S Kissling W Davis JM Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009 39 10 1591 1602 19335931
   PubMed Web of Science ®Google Scholar
• Howes OD Kapur S The dopamine hypothesis of schizophrenia: version III – the final common pathway Schizophr Bull 2009 35 3 549 562 19325164
   PubMed Web of Science ®Google Scholar
• Laruelle M Abi-Dargham A Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies J Psychopharmacol 1999 13 4 358 371 10667612
   PubMed Web of Science ®Google Scholar
• Carlsson A Waters N Waters S Carlsson ML Network interactions in schizophrenia – therapeutic implications Brain Res Brain Res Rev 2000 31 2–3 342 349 10719161
   PubMedGoogle Scholar
• Abi-Dargham A Do we still believe in the dopamine hypothesis? New data bring new evidence Int J Neuropsychopharmacol 2004 7 Suppl 1 S1 S5 14972078
   PubMed Web of Science ®Google Scholar
• Lieberman JA Kane JM Alvir J Provocative tests with psychostimulant drugs in schizophrenia Psychopharmacology (Berl) 1987 91 4 415 433 2884687
   PubMed Web of Science ®Google Scholar
• Kegeles LS Abi-Dargham A Frankle WG Increased synaptic dopamine function in associative regions of the striatum in schizophrenia Arch Gen Psychiatry 2010 67 3 231 239 20194823
   PubMed Web of Science ®Google Scholar
• Laruelle M D’Souza CD Baldwin RM Imaging D2 receptor occupancy by endogenous dopamine in humans Neuropsychopharmacology 1997 17 3 162 174 9272483
   PubMed Web of Science ®Google Scholar
• Fujita M Verhoeff NP Varrone A Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans Eur J Pharmacol 2000 387 2 179 188 10650158
   PubMed Web of Science ®Google Scholar
• Egerton A Chaddock CA Winton-Brown TT Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort Biol Psychiatry 2013 74 2 106 112 23312565
   PubMed Web of Science ®Google Scholar
• McGowan S Lawrence AD Sales T Quested D Grasby P Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study Arch Gen Psychiatry 2004 61 2 134 142 14757589
   PubMed Web of Science ®Google Scholar
• Howes OD Kambeitz J Kim E The nature of dopamine dysfunction in schizophrenia and what this means for treatment Arch Gen Psychiatry 2012 69 8 776 786 22474070
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A Miletich RS Kohn PD Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia Nat Neurosci 2002 5 3 267 271 11865311
   PubMed Web of Science ®Google Scholar
• Collins P Roberts AC Dias R Everitt BJ Robbins TW Perseveration and strategy in a novel spatial self-ordered sequencing task for nonhuman primates: effects of excitotoxic lesions and dopamine depletions of the prefrontal cortex J Cogn Neurosci 1998 10 3 332 354 9869708
   PubMed Web of Science ®Google Scholar
• Williams JM Galli A The dopamine transporter: a vigilant border control for psychostimulant action Handb Exp Pharmacol 2006215 06232
   Google Scholar
• Harrison PJ The neuropathology of schizophrenia. A critical review of the data and their interpretation Brain 1999 122 Pt 4 593 624 10219775
   PubMed Web of Science ®Google Scholar
• Lodge DJ Grace AA Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia Trends Pharmacol Sci 2011 32 9 507 513 21700346
   PubMed Web of Science ®Google Scholar
• Krystal JH Karper LP Seibyl JP Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry 1994 51 3 199 214 8122957
   PubMed Web of Science ®Google Scholar
• Jentsch JD Roth RH The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 1999 20 3 201 225 10063482
   PubMed Web of Science ®Google Scholar
• Javitt DC Zukin SR Recent advances in the phencyclidine model of schizophrenia Am J Psychiatry 1991 148 10 1301 1308 1654746
   PubMed Web of Science ®Google Scholar
• Jenkins TA Harte MK Reynolds GP Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat Neurosci Lett 2010 471 3 144 147 20097262
   PubMed Web of Science ®Google Scholar
• Moghaddam B Adams BW Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats Science 1998 281 5381 1349 1352 9721099
   PubMed Web of Science ®Google Scholar
• Moghaddam B Adams B Verma A Daly D Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J Neurosci 1997 17 8 2921 2927 9092613
   PubMed Web of Science ®Google Scholar
• Sturgeon RD Fessler RG Meltzer HY Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats Eur J Pharmacol 1979 59 3–4 169 179 575093
   PubMed Web of Science ®Google Scholar
• Sams-Dodd F Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats Behav Pharmacol 1995 6 1 55 65 11224312
   PubMed Web of Science ®Google Scholar
• Sams-Dodd F Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia Behav Pharmacol 1996 7 1 3 23 11224390
   PubMed Web of Science ®Google Scholar
• Noda A Noda Y Kamei H Phencyclidine impairs latent learning in mice: interaction between glutamatergic systems and sigma(1) receptors Neuropsychopharmacology 2001 24 4 451 460 11182540
   PubMed Web of Science ®Google Scholar
• Egerton A Brett RR Pratt JA Acute delta9-tetrahydrocannabinol-induced deficits in reversal learning: neural correlates of affective inflexibility Neuropsychopharmacology 2005 30 10 1895 1905 15812570
   PubMed Web of Science ®Google Scholar
• Wang CZ Yang SF Xia Y Johnson KM Postnatal phencyclidine administration selectively reduces adult cortical parvalbumin-containing interneurons Neuropsychopharmacology 2008 33 10 2442 2455 18059437
   PubMed Web of Science ®Google Scholar
• Mohn AR Gainetdinov RR Caron MG Koller BH Mice with reduced NMDA receptor expression display behaviors related to schizophrenia Cell 1999 98 4 427 436 10481908
   PubMed Web of Science ®Google Scholar
• Csicsvari J Hirase H Czurko A Buzsáki G Reliability and state dependence of pyramidal cell-interneuron synapses in the hippocampus: an ensemble approach in the behaving rat Neuron 1998 21 1 179 189 9697862
   PubMed Web of Science ®Google Scholar
• Maccaferri G Dingledine R Control of feedforward dendritic inhibition by NMDA receptor-dependent spike timing in hippocampal interneurons J Neurosci 2002 22 13 5462 5472 12097498
   PubMed Web of Science ®Google Scholar
• Théberge J Bartha R Drost DJ Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers Am J Psychiatry 2002 159 11 1944 1946 12411236
   PubMed Web of Science ®Google Scholar
• Lewis DA Hashimoto T Volk DW Cortical inhibitory neurons and schizophrenia Nat Rev Neurosci 2005 6 312 324 15803162
   PubMed Web of Science ®Google Scholar
• Benes FM Berretta S GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder Neuropsychopharmacology 2001 25 1 1 27 11377916
   PubMed Web of Science ®Google Scholar
• Lewis DA Curley AA Glausier JR Volk DW Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia Trends Neurosci 2012 35 1 57 67 22154068
   PubMed Web of Science ®Google Scholar
• Curley AA Lewis DA Cortical basket cell dysfunction in schizophrenia J Physiol 2012 590 Pt 4 715 724 22219337
   PubMed Web of Science ®Google Scholar
• Curley AA Eggan SM Lazarus MS Huang ZJ Volk DW Lewis DA Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: implications for schizophrenia Neurobiol Dis 2013 50 179 186 23103418
   PubMed Web of Science ®Google Scholar
• Gonzalez-Burgos G Lewis DA NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia Schizophr Bull 2012 38 5 950 957 22355184
   PubMed Web of Science ®Google Scholar
• Beasley CL Zhang ZJ Patten I Reynolds GP Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins Biol Psychiatry 2002 52 7 708 715 12372661
   PubMed Web of Science ®Google Scholar
• Beneyto M Morris HM Rovensky KC Lewis DA Lamina- and cell-specific alterations in cortical somatostatin receptor 2 mRNA expression in schizophrenia Neuropharmacology 2012 62 3 1598 1605 21215273
   PubMed Web of Science ®Google Scholar
• Hashimoto T Volk DW Eggan SM Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia J Neurosci 2003 23 15 6315 6326 12867516
   PubMed Web of Science ®Google Scholar
• Woo TU Whitehead RE Melchitzky DS Lewis DA A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia Proc Natl Acad Sci U S A 1998 95 9 5341 5346 9560277
   PubMed Web of Science ®Google Scholar
• Pierri JN Chaudry AS Woo TU Lewis DA Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects Am J Psychiatry 1999 156 11 1709 1719 10553733
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y Hama K Fast-spiking non-pyramidal cells in the hippocampal CA3 region, dentate gyrus and subiculum of rats Brain Res 1987 425 2 351 355 3427435
   PubMed Web of Science ®Google Scholar
• Gonzalez-Burgos G Lewis DA GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia Schizophr Bull 2008 34 5 944 961 18586694
   PubMed Web of Science ®Google Scholar
• Lodge DJ Behrens MM Grace AA A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia J Neurosci 2009 29 8 2344 2354 19244511
   PubMed Web of Science ®Google Scholar
• Tsuang MT Gilbertson MW Faraone SV The genetics of schizophrenia. Current knowledge and future directions Schizophr Res 1991 4 2 157 171 2039759
   PubMed Web of Science ®Google Scholar
• Tsuang MT Stone WS Faraone SV Schizophrenia: family studies and treatment of spectrum disorders Dialogues in Clinical Neuroscience 2000 2 4 381 391 22033752
   PubMedGoogle Scholar
• Cardno AG Jones LA Murphy KC Dimensions of psychosis in affected sibling pairs Schizophr Bull 1999 25 4 841 850 10667752
   PubMed Web of Science ®Google Scholar
• Kendler KS Twin studies of psychiatric illness. Current status and future directions Arch Gen Psychiatry 1993 50 11 905 915 8215816
   PubMed Web of Science ®Google Scholar
• Sullivan PF Kendler KS Neale MC Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies Arch Gen Psychiatry 2003 60 12 1187 1192 14662550
   PubMed Web of Science ®Google Scholar
• McGuffin P Owen MJ Farmer AE Genetic basis of schizophrenia Lancet 1995 346 8976 678 682 7658823
   PubMed Web of Science ®Google Scholar
• Millar JK Wilson-Annan JC Anderson S Disruption of two novel genes by a translocation co-segregating with schizophrenia Hum Mol Genet 2000 9 9 1415 1423 10814723
   PubMed Web of Science ®Google Scholar
• Debono R Topless R Markie D Black MA Merriman TR Analysis of the DISC1 translocation partner (11q14.3) in genetic risk of schizophrenia Genes Brain Behav 2012 11 7 859 863 22891933
   PubMed Web of Science ®Google Scholar
• Harrison PJ Weinberger DR Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence Mol Psychiatry 2005 10 1 40 68 15263907
   PubMed Web of Science ®Google Scholar
• Craddock N O’Donovan MC Owen MJ The genetics of schizophrenia and bipolar disorder: dissecting psychosis J Med Genet 2005 42 3 193 204 15744031
   PubMed Web of Science ®Google Scholar
• Harrison PJ Owen MJ Genes for schizophrenia? Recent findings and their pathophysiological implications Lancet 2003 361 9355 417 419 12573388
   PubMed Web of Science ®Google Scholar
• Stefansson H Sigurdsson E Steinthorsdottir V Neuregulin 1 and susceptibility to schizophrenia Am J Hum Genet 2002 71 4 877 892 12145742
   PubMed Web of Science ®Google Scholar
• Hosak L Silhan P Hosakova J Genomic copy number variations: A breakthrough in our knowledge on schizophrenia etiology? Neuro Endocrinol Lett 2012 33 2 183 190 22592199
   PubMed Web of Science ®Google Scholar
• Jia P Wang L Meltzer HY Zhao Z Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data Schizophr Res 2010 122 1–3 38 42 20659789
   PubMed Web of Science ®Google Scholar
• Alkelai A Lupoli S Greenbaum L Identification of new schizophrenia susceptibility loci in an ethnically homogeneous, family-based, Arab-Israeli sample FASEB J 2011 25 11 4011 4023 21795503
   PubMed Web of Science ®Google Scholar
• Alkelai A Lupoli S Greenbaum L DOCK4 and CEACAM21 as novel schizophrenia candidate genes in the Jewish population Int J Neuropsychopharmacol 2012 15 4 459 469 21682944
   PubMed Web of Science ®Google Scholar
• Athanasiu L Mattingsdal M Kähler AK Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort J Psychiatr Res 2010 44 12 748 753 20185149
   PubMed Web of Science ®Google Scholar
• Gershon ES Alliey-Rodriguez N Liu C After GWAS: searching for genetic risk for schizophrenia and bipolar disorder Am J Psychiatry 2011 168 3 253 256 21285144
   PubMed Web of Science ®Google Scholar
• Brown R Colter N Corsellis JA Postmortem evidence of structural brain changes in schizophrenia. Differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder Arch Gen Psychiatry 1986 43 1 36 42 2935114
   PubMed Web of Science ®Google Scholar
• Bogerts B Falkai P Greve B Schneider T Pfeiffer U The neuropathology of schizophrenia: past and present J Hirnforsch 1993 34 2 193 205 8228181
   PubMedGoogle Scholar
• Bogerts B Lieberman JA Ashtari M Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia Biol Psychiatry 1993 33 4 236 246 8471676
   PubMed Web of Science ®Google Scholar
• Gonzalez-Burgos G Hashimoto T Lewis DA Alterations of cortical GABA neurons and network oscillations in schizophrenia Curr Psychiatry Rep 2010 12 4 335 344 20556669
   PubMed Web of Science ®Google Scholar
• Hill K Mann L Laws KR Stephenson CM Nimmo-Smith I McKenna PJ Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies Acta Psychiatr Scand 2004 110 4 243 256 15352925
   PubMed Web of Science ®Google Scholar
• Moore H Jentsch JD Ghajarnia M Geyer MA Grace AA A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia Biol Psychiatry 2006 60 3 253 264 16581031
   PubMed Web of Science ®Google Scholar
• Lodge DJ Grace AA Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia Behav Brain Res 2009 204 2 306 312 19716984
   PubMed Web of Science ®Google Scholar
• Bayer SA Altman J Russo RJ Zhang X Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat Neurotoxicology 1993 14 1 83 144 8361683
   PubMed Web of Science ®Google Scholar
• Lodge DJ Grace AA Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia J Neurosci 2007 27 42 11424 11430 17942737
   PubMed Web of Science ®Google Scholar
• Perez SM Lodge DJ Aberrant dopamine D2-like receptor function in a rodent model of schizophrenia J Pharmacol Exp Ther 2012 343 2 288 295 22859862
   PubMed Web of Science ®Google Scholar
• Perez SM Shah A Asher A Lodge DJ Hippocampal deep brain stimulation reverses physiological and behavioural deficits in a rodent model of schizophrenia Int J Neuropsychopharmacol 2013 16 6 1331 1339 23190686
   PubMed Web of Science ®Google Scholar
• Perez SM Lodge DJ Hippocampal interneuron transplants reverse aberrant dopamine system function and behavior in a rodent model of schizophrenia Mol Psychiatry 2013 18 11 1193 1198 23979606
   PubMed Web of Science ®Google Scholar
• Floresco SB Todd CL Grace AA Glutamatergic afferents from the hip-pocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons J Neurosci 2001 21 13 4915 4922 11425919
   PubMed Web of Science ®Google Scholar
• Floresco SB West AR Ash B Moore H Grace AA Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission Nat Neurosci 2003 6 9 968 973 12897785
   PubMed Web of Science ®Google Scholar
• Grace AA Bunney BS Intracellular and extracellular electrophysiology of nigral dopaminergic neurons – 1. Identification and characterization Neuroscience 1983 10 2 301 315 6633863
   PubMed Web of Science ®Google Scholar
• Lodge DJ Grace AA The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation Neuropsychopharmacology 2006 31 7 1356 1361 16319915
   PubMed Web of Science ®Google Scholar
• Schobel SA Lewandowski NM Corcoran CM Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders Arch Gen Psychiatry 2009 66 9 938 946 19736350
   PubMed Web of Science ®Google Scholar
• Heckers S Rauch SL Goff D Impaired recruitment of the hippocampus during conscious recollection in schizophrenia Nat Neurosci 1998 1 4 318 323 10195166
   PubMed Web of Science ®Google Scholar
• Lipska BK Jaskiw GE Weinberger DR Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia Neuropsychopharmacology 1993 9 1 67 75 8397725
   PubMed Web of Science ®Google Scholar
• Swerdlow NR Halim N Hanlon FM Platten A Auerbach PP Lesion size and amphetamine hyperlocomotion after neonatal ventral hippocampal lesions: more is less Brain Res Bull 2001 55 1 71 77 11427340
   PubMed Web of Science ®Google Scholar
• Zhang ZJ Reynolds GP A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia Schizophr Res 2002 55 1–2 1 10 11955958
   PubMed Web of Science ®Google Scholar
• Shah A Lodge DJ A loss of hippocampal perineuronal nets produces deficits in dopamine system function: relevance to the positive symptoms of schizophrenia Transl Psychiatry 2013 3 e215 23321812
   PubMed Web of Science ®Google Scholar
• Gill KM Lodge DJ Cook JM Aras S Grace AA A novel α5GABA(A) R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia Neuropsychopharmacology 2011 36 9 1903 1911 21562483
   PubMed Web of Science ®Google Scholar
• Gastambide F Cotel MC Gilmour G O’Neill MJ Robbins TW Tricklebank MD Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator Neuropsychopharmacology 2012 37 4 1057 1066 22129780
   PubMed Web of Science ®Google Scholar
• Volz A Khorsand V Gillies D Leucht S Benzodiazepines for schizophrenia Cochrane Database Syst Rev 2007 CD006391 17253592
   PubMed Web of Science ®Google Scholar
• Tiihonen J Suokas JT Suvisaari JM Haukka J Korhonen P Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia Arch Gen Psychiatry 2012 69 5 476 483 22566579
   PubMed Web of Science ®Google Scholar
• McKernan RM Whiting PJ Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci 1996 19 4 139 143 8658597
   PubMed Web of Science ®Google Scholar
• Quirk K Blurton P Fletcher S [3H]L-655,708, a novel ligand selective for the benzodiazepine site of GABAA receptors which contain the alpha 5 subunit Neuropharmacology 1996 35 9–10 1331 1335 9014149
   PubMed Web of Science ®Google Scholar
• Pritchett DB Sontheimer H Shivers BD Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology Nature 1989 338 6216 582 585 2538761
   PubMed Web of Science ®Google Scholar
• Heldt SA Ressler KJ Forebrain and midbrain distribution of major benzodiazepine-sensitive GABAA receptor subunits in the adult C57 mouse as assessed with in situ hybridization Neuroscience 2007 150 2 370 385 17950542
   PubMed Web of Science ®Google Scholar
• Ramos B Lopez-Tellez JF Vela J Expression of alpha 5 GABAA receptor subunit in developing rat hippocampus Brain Res Dev Brain Res 2004 151 1–2 87 98
   Google Scholar
• Mayberg HS Lozano AM Voon V Deep brain stimulation for treatment-resistant depression Neuron 2005 45 5 651 660 15748841
   PubMed Web of Science ®Google Scholar
• Greenberg BD Pinto A Mancebo M Eisen J Rasmussen SA Obsessive-compulsive disorder: recognition across medical settings, and treatments from behavior therapy to neurosurgery Med Health R I 2006 89 5 162 165 16764296
   PubMedGoogle Scholar
• Benabid AL Pollak P Gervason C Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus Lancet 1991 337 8738 403 406 1671433
   PubMed Web of Science ®Google Scholar
• Wyckhuys T De Smedt T Claeys P High frequency deep brain stimulation in the hippocampus modifies seizure characteristics in kindled rats Epilepsia 2007 48 8 1543 1550 17381435
   PubMed Web of Science ®Google Scholar
• Boon P Vonck K De Herdt V Deep brain stimulation in patients with refractory temporal lobe epilepsy Epilepsia 2007 48 8 1551 1560 17726798
   PubMed Web of Science ®Google Scholar
• Grace AA Floresco SB Goto Y Lodge DJ Regulation of firing of dopaminergic neurons and control of goal-directed behaviors Trends Neurosci 2007 30 5 220 227 17400299
   PubMed Web of Science ®Google Scholar